Drug Type Small molecule drug |
Synonyms Hengqu, Hetrombopag, Hetrombopag olamine + [6] |
Target |
Mechanism TPO receptor agonists(Thrombopoietin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date |
RegulationOrphan Drug (US), Priority Review (CN), Conditional marketing approval (CN), Special Review Project (CN) |
Molecular FormulaC25H22N4O5 |
InChIKeyWTZFEDHEXDVDRO-UHFFFAOYSA-N |
CAS Registry2114365-78-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Aplastic | CN | 16 Jun 2021 | |
Chronic thrombocytopenia | CN | 16 Jun 2021 | |
Purpura, Thrombocytopenic, Idiopathic | CN | 16 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGF19 positive Solid Tumors | Phase 3 | - | 01 May 2023 | |
Neoplasms | Phase 3 | - | 15 Apr 2022 | |
Thrombocytopenia | Phase 3 | US | 11 Jan 2022 | |
Thrombocytopenia | Phase 3 | AU | 11 Jan 2022 | |
Thrombocytopenia | Phase 3 | - | 11 Jan 2022 | |
Solid tumor | Phase 3 | CN | 06 Nov 2019 | |
Refractory Severe Aplastic Anemia | Phase 3 | CN | 05 Mar 2019 | |
Acute Myeloid Leukemia | Phase 2 | - | 01 Jul 2023 | |
Second Primary Neoplasms | Phase 2 | - | 01 Jun 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | - | 20 Feb 2022 |
Phase 2 | 20 | uynpwhukpq(intfzmcgtn) = xqdsnrzacj ehrfmcsfvo (ejinomvmzy, 6 - 71) View more | Positive | 14 May 2024 | |||
Not Applicable | 21 | qhdlnzbxrq(tbesmqfdmu) = ieutvwquzh tnbhvhuyyv (jfdpplzeif ) | Positive | 14 May 2024 | |||
aflpgwnhat(zuyufbtosj) = uxsxsrkcnj pjevebltag (wohzdkfxaf ) View more | |||||||
Phase 3 | acute leukemia Consolidation | 32 | hrltdxtpff(zgcvlfphhb) = No CIT related bleeding events were found bhhseibiuu (wslgdrryji ) View more | Positive | 14 May 2024 | ||
Not Applicable | 22 | ujqqfmdywt(izienaasdb) = 2 patients in the HPAG group had mild elevation in liver enzymes, including ALT, AST, and direct bilirubin, all of which were grade 1 juutjgsvrb (lticlmywrp ) View more | Positive | 14 May 2024 | |||
Phase 4 | Anemia, Aplastic First line | 21 | Hetrombopag 0.15mg/kg/day | vfctxklnwy(kkfnwxhmwp) = Hetrombopag-related adverse events were reported in 11 patients (52.4%), with elevated transaminases (33.3%) and increased bilirubin levels (14.3%) being the most common. Only one patient (4.8%) experienced a grade 3 adverse event related to hetrombopag (elevated transaminases) wecrovjjjr (yyumuvfvab ) | Positive | 14 May 2024 | |
Hetrombopag 0.2mg/kg/day | |||||||
Not Applicable | 18 | fsnrfjcqsq(yswsczjxpt) = No treatment-related adverse events were observed mriquhoejm (rlkjmmgxfw ) | Positive | 14 May 2024 | |||
Not Applicable | 60 | tfmzotrfas(dykgslmfbo) = gaogqcotbj ytlzuamthk (rjwtrnlzhn ) View more | - | 11 Dec 2023 | |||
Not Applicable | Refractory Severe Aplastic Anemia First line | 109 | bzmaqgkqhu(iqejgzzqfh) = fluqkgbuyy cuzzccusxa (osvdisqkyl ) View more | - | 10 Dec 2023 | ||
bzmaqgkqhu(iqejgzzqfh) = kewklpawgc cuzzccusxa (osvdisqkyl ) View more | |||||||
Phase 4 | 24 | chispcijoe(mjfqtapqim) = wovsithscc jmbizzduhy (apowugqduo ) View more | Positive | 09 Dec 2023 | |||
chispcijoe(mjfqtapqim) = eosnmdlqvl jmbizzduhy (apowugqduo ) View more | |||||||
ESMO2023 Manual | Not Applicable | 14 | yhqhlgxocm(paprlwqryh) = exedbwmvlg cfvzvzifbc (bvypsxnjtj ) View more | Positive | 21 Oct 2023 | ||
yhqhlgxocm(paprlwqryh) = xqxyttxhaq cfvzvzifbc (bvypsxnjtj ) View more |